While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

ST. PAUL, MN / ACCESS Newswire / December 4, 2025 / Odyssey Transfer and Trust Company (“Odyssey” or the “Company“), a leading North American transfer agent and trust company that is scaling rapidly ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...

Investing.com -- Q32 Bio Inc (NASDAQ:QTTB) stock surged 94% in premarket trading Monday after the clinical-stage biotechnology company announced the sale of its Phase 2 complement inhibitor, ADX-097, ...

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...

After a busy offseason, the Golden State Warriors have added several new pieces to their roster as they aim for another championship run. With Jonathan Kuminga’s contract situation finally settled, ...